USPTO serial 99180190
CGT 360
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- RODRIGUEZ FONTANE, KIARA
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with CGT 360?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cynthia A. Moyer
Cynthia A. Moyer Fredrikson & Byron, P.A.60 South Sixth StreetSuite 1500Minneapolis, MN 55402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business management and consulting services for the health care industry, namely, business management of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies for health plans, health insurers, self-funded plans, and reinsurers; Business management and administration in the field of healthcare, namely, development, creation and implementation of health care provider networks in the field of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Business administration of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapy programs; Business data analytics services, namely, health data collection and analysis in the nature of data compiling and analyzing to provide information and metrics regarding health insurance claims to help clients forecast outcomes, business risk, and expenses; Data acquisition and collection for insurance services for business purposes; Business research in the field of health care relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapy programs; Medical cost management relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies. | ACTIVE | — |
| 036 | Financial consultation to healthcare providers, namely, providing assistance in managing health care expenses related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Group financial risk management services, namely, health care expense risk pooling and financial risk management services related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Providing financial and insurance information and consulting in the fields of insurance and healthcare preferred provider networks relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; preferred provider network programs, namely, administration of medical services in the nature of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies provided through a network of health care providers; Preferred provider network services, namely, administering medical benefits in the nature of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies provided through a network of health care providers under an insurance plan | ACTIVE | — |
| 044 | Consulting services in the field of medical care, namely, developing medical treatment policies related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Providing medical information in the field of cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Concierge medical services, namely, personal health care concierge services to guide patients through medical treatments related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Medical consultations, namely, consulting, advising, and assisting patients and families with navigating the complex healthcare system relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Providing information in the field of health care, namely, models of care, medical practice, and health care delivery and outcomes, all relating to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies; Healthcare services, namely, provision of medical care related to cell and gene therapies, solid organ and bone marrow transplants, and other complex medical therapies provided by a network of providers through an integrated, coordinated model of care delivery, with communication of best practices among the network, and the sharing of quality metrics with participants in the network; Consulting regarding healthcare services provided through an integrated and comprehensive model of care delivery featuring protocols, standards, staff training and education, implementation measures for management, care coordination, and disease management all in the field of cell and gene therapy, solid organ and bone marrow transplants, and other complex medical therapies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Emerging Therapy Solutions, Inc.
- Other trademarks owned by Emerging Therapy Solutions, Inc.
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 044
- Similar marks named CGT 360
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 16, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 16, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 10, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 18, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 13, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 13, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 13, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 4, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2026 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 21, 2026 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Mar 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 9, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 9, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 9, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 26, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 21, 2025 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 21, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 12, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 12, 2025 | NWAP | NEW APPLICATION ENTERED | — |